SCHEMBL6448129

SCHEMBL6448129

N[C@@H](CC(C(=O)O)c1ccccc1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 2/20 0.62
GRM3 Q14832 2/20 0.62
SLC1A1 P43005 3/20 0.53
SLC1A2 P43004 2/20 0.53
SLC1A3 P43003 1/20 0.53
ALPI P09923 1/20 0.52
PKM P14618 1/20 0.52
PTGS1 P23219 1/20 0.52
XIAP P98170 1/20 0.52
SLC7A5 Q01650 1/20 0.52
CYP2C19 P33261 1/20 0.52
KYNU Q16719 1/20 0.51
GRIK1 P39086 4/20 0.47
EPHX1 P07099 1/20 0.47
GRIK2 Q13002 3/20 0.46
CYP2D6 P10635 1/20 0.45
SRC P12931 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5286288 1.00 GRM2 (0.62) GRM2GRM3SLC1A1SLC1A2SLC1A3
SCHEMBL6158397 0.89 GRM2 (0.59) GRM2GRM3SLC1A1SLC1A2SLC1A3
SCHEMBL8558695 0.87 GRM2 (0.57) GRM2GRM3SLC1A1SLC1A2SLC1A3
SCHEMBL28640680 0.86 CYP2C19 (0.53) GRM2GRM3ALPIPKMPTGS1
SCHEMBL7973743 0.85 CYP2C19 (0.61) GRM2GRM3CYP2C19EPHX1CYP2D6
SCHEMBL5282418 0.83 GRM2 (0.79) GRM2GRM3SLC1A1SLC1A2SLC1A3
SCHEMBL29182085 0.81 MMP8 (0.48) GRM2GRM3CYP2C19
SCHEMBL10150939 0.81 CYP2C19 (0.57) GRM2GRM3CYP2C19EPHX1CYP2D6
SCHEMBL9065063 0.80 KYNU (0.70) GRM2GRM3SLC1A1SLC1A2SLC1A3
SCHEMBL9065025 0.80 KYNU (0.70) GRM2GRM3SLC1A1SLC1A2SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118178053-A Degradable bone scaffold with piezoelectric effect and preparation method thereof 佛山科学技术学院 2024-06-14 CN claimed
CN-118178053-A Degradable bone scaffold with piezoelectric effect and preparation method thereof 佛山科学技术学院 2024-06-14 CN disclosed
US-20050256095-A1 Asthma and colitis treatment methods BIOVIE INC. 2005-11-17 US disclosed
CN-1109032-C Compounds analogous to thalidomide from class comprising piperidine-2,6-diones GRUENENTHAL GMBH (DE) 2003-05-21 CN disclosed
US-6110941-A AN IMMUNOMODULATOR MODULATING THE IMMUNE RESPONSE OF A MAMMAL, INHIBITING ANTIGEN-INDUCED SYNTHESIS OF INTERLEUKIN-2 GRUENENTHAL GMBH (DE) 2000-08-29 US disclosed
CN-1190096-A Compounds analogous to thalidomide from class comprising piperidine-2,6-diones GRUENENTHAL GMBH (DE) 1998-08-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256095-A1 Asthma and colitis treatment methods HSD3B1, HSD17B1, HSD11B1 GRM2 2799/4885GRM3 823/4885SLC1A1 4693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.